{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:17:54Z","timestamp":1793812674518,"version":"4.6.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.vaccine.2019.04.043","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T16:36:04Z","timestamp":1555691764000},"page":"2915-2924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease"],"prefix":"10.1016","volume":"37","author":[{"given":"Diane M.","family":"Da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Skeate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Chavez-Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim P.","family":"L\u00fchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiun-Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Mao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Martin","family":"Kast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KinKai","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2019.04.043_b0005","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0010","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0015","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.ejca.2015.06.001","article-title":"Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions","volume":"51","author":"Serrano","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2019.04.043_b0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2019.04.043_b0025","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0030","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/21645515.2015.1136039","article-title":"Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases","volume":"12","author":"Skeate","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.04.043_b0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pvr.2017.12.006","article-title":"Therapeutic vaccines for high-risk HPV-associated diseases","volume":"5","author":"Chabeda","year":"2018","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2019.04.043_b0040","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1158\/0008-5472.CAN-05-0958","article-title":"Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects","volume":"65","author":"Liao","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2019.04.043_b0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0198-8859(97)00081-5","article-title":"Delivery of antigens to the MHC class I pathway using bacterial toxins","volume":"54","author":"Goletz","year":"1997","journal-title":"Human Immunol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.smim.2010.04.007","article-title":"Adjuvants for cancer vaccines","volume":"22","author":"Dubensky","year":"2010","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0055","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/S0264-410X(00)00118-3","article-title":"Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity","volume":"18","author":"Marciani","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0060","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1016\/S0264-410X(03)00298-6","article-title":"Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100","volume":"21","author":"Marciani","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0065","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0264-410X(00)00195-X","article-title":"Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates","volume":"19","author":"Kim","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0070","doi-asserted-by":"crossref","first-page":"13699","DOI":"10.1073\/pnas.202427599","article-title":"On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines","volume":"99","author":"Ragupathi","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2019.04.043_b0075","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1016\/S0264-410X(03)00438-9","article-title":"Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis","volume":"21","author":"Zhang","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0080","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/978-1-4615-1823-5_22","article-title":"Structural and immunological characterization of the vaccine adjuvant QS-21","volume":"6","author":"Kensil","year":"1995","journal-title":"Pharm Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0085","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4049\/jimmunol.148.5.1519","article-title":"Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine","volume":"148","author":"Wu","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0090","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1016\/j.vaccine.2005.01.072","article-title":"A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21","volume":"23","author":"Slovin","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0095","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.04.043_b0100","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1073\/pnas.161293498","article-title":"Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition","volume":"98","author":"Bauer","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2019.04.043_b0105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.043_b0110","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U","article-title":"Identification of CpG oligonucleotide sequences with high induction of IFN-alpha\/beta in plasmacytoid dendritic cells","volume":"31","author":"Krug","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0115","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/eji.1830230929","article-title":"Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells","volume":"23","author":"Feltkamp","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0120","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.1158\/1078-0432.CCR-09-0645","article-title":"Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors","volume":"15","author":"Smith","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2019.04.043_b0125","doi-asserted-by":"crossref","first-page":"15953","DOI":"10.1016\/S0021-9258(18)71572-X","article-title":"Domain II mutants of Pseudomonas exotoxin deficient in translocation","volume":"264","author":"Jinno","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2019.04.043_b0130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1073\/pnas.87.1.308","article-title":"Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity","volume":"87","author":"Chaudhary","year":"1990","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2019.04.043_b0135","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2007.06.031","article-title":"DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens","volume":"107","author":"Huang","year":"2007","journal-title":"Gynecologic Oncol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.gt.3302646","article-title":"A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects","volume":"13","author":"Peng","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2019.04.043_b0145","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1158\/0008-5472.641.65.2","article-title":"Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein","volume":"65","author":"Preville","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2019.04.043_b0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/abbs\/gmt121","article-title":"De-oncogenic HPV E6\/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin","volume":"46","author":"Chen","year":"2014","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.vaccine.2019.04.043_b0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4110\/in.2015.15.2.51","article-title":"Recent advances of vaccine adjuvants for infectious diseases","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw"},{"key":"10.1016\/j.vaccine.2019.04.043_b0160","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2019.04.043_b0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the Adjuvant System story","volume":"13","author":"Garcon","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.04.043_b0170","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.vaccine.2009.01.091","article-title":"Advances in saponin-based adjuvants","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0264-410X(91)90262-5","article-title":"Genetically-engineered subunit vaccine against feline leukaemia virus: protective immune response in cats","volume":"9","author":"Marciani","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0180","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0264-410X(96)00293-9","article-title":"Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations","volume":"15","author":"Newman","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0185","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers","volume":"26","author":"Vandepapeliere","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0190","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1016\/j.vaccine.2007.06.005","article-title":"Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine","volume":"25","author":"Santos","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0195","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/S0264-410X(00)00415-1","article-title":"QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans","volume":"19","author":"Evans","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0200","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/CJI.0b013e3182917f59","article-title":"A phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma","volume":"36","author":"Amato","year":"2013","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2019.04.043_b0205","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/CJI.0000000000000029","article-title":"A Phase I\/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-alpha and interleukin-2 in patients with renal cell carcinoma","volume":"37","author":"Amato","year":"2014","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2019.04.043_b0210","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.043_b0215","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.addr.2008.12.008","article-title":"Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists","volume":"61","author":"Vollmer","year":"2009","journal-title":"Advanced Drug Delivery Rev"},{"key":"10.1016\/j.vaccine.2019.04.043_b0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/10428194.2011.608451","article-title":"Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia","volume":"53","author":"Zent","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.vaccine.2019.04.043_b0225","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.2010.32.8971","article-title":"Randomized phase III trial of paclitaxel\/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer","volume":"29","author":"Hirsh","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0230","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0235","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00262-015-1770-9","article-title":"A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal\/subcutaneous sites","volume":"65","author":"Slingluff","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2019.04.043_b0240","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0245","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1128\/JVI.07069-11","article-title":"Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6\/E7 deregulation and the loss of contact inhibition in neoplastic progression","volume":"86","author":"Isaacson Wechsler","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.043_b0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/156800907780006869","article-title":"Mechanisms used by human papillomaviruses to escape the host immune response","volume":"7","author":"Kanodia","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.vaccine.2019.04.043_b0255","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ijc.31027","article-title":"Immune evasion mechanisms of human papillomavirus: an update","volume":"142","author":"Steinbach","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2019.04.043_b0260","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00262-012-1259-8","article-title":"TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers","volume":"61","author":"Barrios","year":"2012","journal-title":"Cancer Immunol Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:31:59Z","timestamp":1759401119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19305079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":52,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0264410X19305079"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}